Research programme: DYRK1A inhibitors - Fresh Tracks Therapeutics
Alternative Names: DYRK1A Inhibitor Programme - Fresh Tracks Therapeutics/Voronoi; Next Generation DYRK1A Inhibitors - Fresh Tracks TherapeuticsLatest Information Update: 26 Sep 2023
At a glance
- Originator Voronoi
- Developer Fresh Tracks Therapeutics
- Class Anti-inflammatories; Antidementias; Antihyperglycaemics; Antipsoriatics; Antirheumatics; Neuroprotectants; Skin disorder therapies; Small molecules
- Mechanism of Action DYRK kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Alzheimer's disease; Atopic dermatitis; Down syndrome; Hidradenitis suppurativa; Inflammatory bowel diseases; Neurodegenerative disorders; Osteoarthritis; Psoriasis; Rheumatoid arthritis; Systemic lupus erythematosus; Type 1 diabetes mellitus